It is also worth noting that patients with KRAS/SMARCA4‐comutated NSCLC have been shown to have a worse prognosis than those with only SMARCA4—and not KRAS—alterations [35]. The gene discussed is SMARCA4; the disease is non-small cell lung carcinoma.